SCHEMBL3144249

SCHEMBL3144249

O=C(NCCCN1CCC(N2CCCCC2)CC1)c1ccc(S(=O)(=O)Nc2ccccc2Oc2ccc(Br)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 6/20 0.50
L3MBTL3 Q96JM7 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
ALDH1A1 P00352 4/20 0.47
HPGD P15428 1/20 0.47
KDM4E B2RXH2 1/20 0.44
PKM P14618 1/20 0.44
BDKRB1 P46663 1/20 0.44
KCNH2 Q12809 1/20 0.44
SLC9A3 P48764 2/20 0.44
CHRM4 P08173 1/20 0.44
DRD2 P14416 1/20 0.44
DRD4 P21917 1/20 0.44
DRD3 P35462 1/20 0.44
METAP2 P50579 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3148923 0.94 L3MBTL3 (0.52) CCR2L3MBTL3L3MBTL1ALDH1A1KDM4E
SCHEMBL3140012 0.91 CCR2 (0.53) CCR2L3MBTL3L3MBTL1ALDH1A1KDM4E
SCHEMBL3147720 0.91 CCR2 (0.52) CCR2L3MBTL3L3MBTL1ALDH1A1KDM4E
SCHEMBL3153072 0.90 CCR2 (0.50) CCR2L3MBTL3L3MBTL1ALDH1A1KDM4E
SCHEMBL3153662 0.89 CCR2 (0.49) CCR2L3MBTL3L3MBTL1ALDH1A1HPGD
SCHEMBL3149074 0.89 CCR2 (0.59) CCR2L3MBTL3L3MBTL1ALDH1A1KDM4E
SCHEMBL3049934 0.89 L3MBTL3 (0.49) CCR2L3MBTL3L3MBTL1ALDH1A1KDM4E
SCHEMBL3153333 0.85 CCR2 (0.51) CCR2L3MBTL3L3MBTL1ALDH1A1KDM4E
SCHEMBL3139721 0.84 CCR2 (0.55) CCR2L3MBTL3L3MBTL1KCNH2
SCHEMBL3149383 0.84 L3MBTL3 (0.44) CCR2L3MBTL3L3MBTL1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074083-B1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-06-19 EP claimed
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-03-25 US claimed
EP-2074083-B1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-06-19 EP disclosed
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS BDKRB1, BDKRB2, TRPV1 CCR2 417/4885L3MBTL3 3807/4885L3MBTL1 3132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.